U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H18O11
Molecular Weight 422.3396
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MANGIFERIN

SMILES

[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C2=C(O)C3=C(OC4=C(C=C(O)C(O)=C4)C3=O)C=C2O

InChI

InChIKey=AEDDIBAIWPIIBD-ZJKJAXBQSA-N
InChI=1S/C19H18O11/c20-4-11-15(25)17(27)18(28)19(30-11)12-8(23)3-10-13(16(12)26)14(24)5-1-6(21)7(22)2-9(5)29-10/h1-3,11,15,17-23,25-28H,4H2/t11-,15-,17+,18-,19+/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H18O11
Molecular Weight 422.3396
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Mangiferin, a bioactive compound derived primarily from Anacardiaceae and Gentianaceae families and found in mangoes and honeybush tea, has been extensively studied for its therapeutic properties. Mangiferin has shown promising chemotherapeutic and chemopreventative potential. In traditional medicine, different cultures have cultivated and processed mangiferin rich plants for the treatment of a range of illnesses including cardiovascular disease, diabetes, infection and cancer. Mangiferin is primarily implicated in down-regulating inflammation, causing cell cycle arrest, reducing proliferation/metastasis, promoting apoptosis in malignant cells and protecting against oxidative stress and DNA damage. Mangiferin also enhances the capacity of the monocyte-macrophage system and possesses antibacterial activity against gram-positive and gram-negative bacteria.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
3.2 µM [IC50]
358.54 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
19.94 ng/mL
0.2 g single, oral
MANGIFERIN plasma
Homo sapiens
34.7 ng/mL
0.3 g single, oral
MANGIFERIN plasma
Homo sapiens
38.64 ng/mL
0.9 g single, oral
MANGIFERIN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
167.9 ng × h/mL
0.2 g single, oral
MANGIFERIN plasma
Homo sapiens
269.35 ng × h/mL
0.3 g single, oral
MANGIFERIN plasma
Homo sapiens
415.14 ng × h/mL
0.9 g single, oral
MANGIFERIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
4.47 h
0.2 g single, oral
MANGIFERIN plasma
Homo sapiens
8.8 h
0.3 g single, oral
MANGIFERIN plasma
Homo sapiens
7.85 h
0.9 g single, oral
MANGIFERIN plasma
Homo sapiens

Doses

Drug as perpetrator​

PubMed

Sample Use Guides

In Vivo Use Guide
Mouse tumor xenograft model: Mangiferin (10, 50 and 100 mg/kg) was intraperitoneally injected into the mice, and the therapy lasted for 2 weeks
Route of Administration: Intraperitoneal
In Vitro Use Guide
Mangiferin (30–300 uM), isolated from A. asphodeloides, specifi- cally inhibited MMP-9 gene expression in PMA-stimulated human astroglioma U87MG, U373MG, and CRT-MG cells. Mangiferin (80 uM) could inhibit the proliferation of HL-60, block the cell cycle progression in G2/M phase, and significantly increased the expressions of CDC2 mRNA and Cyclin B1 mRNA of HL-60 cells.
Substance Class Chemical
Record UNII
1M84LD0UMD
Record Status Validated (UNII)
Record Version